News

Luna Labs’ MedSim Product Lines Acquired by Integrated Medcraft

Integrated MedCraft LLC today announced it has acquired the TrueClot and Dislotech product lines from Luna Labs. This announcement is more than a successful transaction. It is an example of innovation being accelerated with the right strategic partner.

We built Luna Labs with a clear mission to incubate, accelerate, and grow technologies to the point where they are poised to achieve their full potential. This acquisition demonstrates that our strategy is working as intended.

What started as an SBIR project to create a realistic blood simulant for the Department of Defense has evolved into TrueClot Bleeding Control Training Products. Routinely used to train professional first responders, law enforcement, and combat medics, the market opportunity is bigger than our company can address alone. This acquisition ensures these products will reach the scale and impact they deserve.

Dislotech Joint Reduction Trainers are also ready for growth, offering athletic trainers and medical professionals the opportunity for hands-on joint reduction training prior to practice on patients.

“I am proud of what our Luna Labs’ MedSim team has accomplished,” said Michael Danilich, PhD, Sr. VP of Operations at Luna Labs, and Principal Investigator, TrueClot. “We didn’t just create products, we created new training standards. It’s been rewarding to watch TrueClot grow from a concept to a suite of tools trusted around the world – that’s the kind of impact we strive to achieve.”

This evolution required relentless determination from our development, operations, sales, marketing, and manufacturing teams. They built the most realistic bleeding control and joint reduction training tools available, and their work set a new benchmark for emergency responder training. Congratulations to Brad Day, Kevin Tate, Joe Cattell-Gordon, Ron Wenzel, Keyanna Grayson, Dana Rich, Lianne Landers, Kelley Virgilio, Matt Patterson, Christopher Tison, PhD, MBA, and many others who contributed to this success.

The transition will be seamless with operations, personnel, and manufacturing staying in Charlottesville. TrueClot and Dislotech products will be sold as part of Integrated Medcraft’s full product portfolio and available to emergency response training markets worldwide.

 

Read more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and